DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

NCT05496595 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Review of Data, and our other compound is a better option

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: DCBY02

Sponsor

DynamiCure Biotechnology